Pooled extended-survival data from two trials including formerly untreated 563 patients who had received BRAF inhibitor dabrafenib plus MEK inhibitor trametinib in the COMBI-d and COMBI-v trials were investigated by the experts in order to determine, in metastatic melanoma, five-year outcomes with dabrafenib plus trametinib.
Archive | Scientific Publications
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Posted in Melanoma News, Publications, Scientific Publications
No association between smoking and sentinel lymph node metastasis and survival in cutaneous melanoma
This retrospective cohort study was undertaken to determine if smoking was correlated with a higher rate of sentinel lymph node (SLN) metastasis and worse survival in cutaneous melanoma patients using a propensity score matching analysis.
Posted in Melanoma News, Publications, Scientific Publications
The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis
Via this meta-analysis, researchers assessed the activity and efficacy of the following strategies to treat patients with melanoma brain metastases: targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy (MI) in combination with radiotherapy (CRI) or not in combination.
Posted in Melanoma News, Publications, Scientific Publications
Melanoma Journal Articles for July 2019
Please click on the link to see a list of melanoma journal citations the crossed the MRV desk this month.
Posted in Melanoma News, Publications, Scientific Publications
